Skip to Content


Pediatric Parenteral Multivitamin Products; Drug Efficacy Study Implementation; Announcement of Marketing Conditions; Correction

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble


Food and Drug Administration, HHS.


Notice; correction.


The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of January 26, 2000 (65 FR 4253). The document announced the conditions for marketing pediatric parenteral multivitamin drug products for the indications for which they are Start Printed Page 20826now regarded as effective. The document was published with an inadvertent error. This document corrects that error.

Start Further Info


Mary E. Catchings, Center for Drug Evaluation and Research (HFD-7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2041.

End Further Info End Preamble Start Supplemental Information


In FR Doc. 00-1787 appearing on page 4253 in the Federal Register of Wednesday, January 26, 2000, the following correction is made:

On page 4255, in the first column, in paragraph B.2.(a), beginning in the second line, the sentence “Caution: Federal law prohibits dispensing without prescription” is corrected to read “Rx only.”

This change is made in accordance with section 126(a) of the Food and Drug Modernization Act of 1997. Section 126(a) modified section 503(b)(4) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353(b)(4)).

Start Signature

Dated: April 7, 2000.

William K. Hubbard,

Senior Associate Commissioner for Policy, Planning, and Legislation.

End Signature End Supplemental Information

[FR Doc. 00-9580 Filed 4-17-00; 8:45 am]